Search

everythinglearnresearchcommunity

for

Search:↓

5-alpha reductase inhibitors may cause sexual side effects, breast complications, and other health risks in men with hair loss.

Dihydrotestosterone gel before hypospadias surgery led to less scarring but raised concerns about potential psychological effects and skin changes.

Skin cells can naturally limit the growth of cancerous changes by balancing cell renewal and differentiation.

Mutations in the androgen receptor gene cause Androgen Insensitivity Syndrome, affecting sexual development.

Using finasteride or dutasteride may cause long-lasting erectile dysfunction.

The assay effectively detects hormonal activity of certain chemicals.

A man's rare adrenal tumor caused feminization and white hair, was removed surgically, and improved after treatment.

The balance between cell renewal and differentiation controls the growth of cancerous cells in mouse skin.

Clascoterone safely promotes hair growth similar to minoxidil.

Disrupting the Tsc2 gene in certain cells leads to thicker skin, larger hair, and changes in hair growth signaling, which can be partly reversed with specific treatment.

A point mutation in the androgen receptor gene causes complete androgen insensitivity.

5α-reductase inhibitors increase the risk of sexual dysfunction, especially in men with enlarged prostate.

Short-term finasteride use likely doesn't harm male fertility.

Men with early balding may have a higher risk of prostate issues, and surgery for prostate cancer has a slight survival benefit over radiation.

Hair loss drugs like finasteride may cause lasting sexual and mood side effects, and more research is needed to understand these risks.

Some patients may experience lasting sexual dysfunction, depression, and other side effects from 5α-reductase inhibitor therapy.

Testosterone reduces heart damage and inflammation after injury.

Finasteride may cause infertility in rats by affecting epididymis and sperm function.

Post-orchidectomy semen has better DNA integrity for fertility treatments.

Testosterone and letrozole treatment speeds up puberty in boys with delayed development.

Higher androgen levels during puberty are linked to shorter adult height in boys with Silver-Russell syndrome.

A stronger dual 5α-reductase inhibitor could improve treatment for benign prostatic hyperplasia by further reducing DHT levels.

MK-0773 is a moderate inhibitor of the SRD5A2 enzyme.

Male cells need DHT to respond to testosterone, while female cells do not.

Stiripentol shows promise as a potential treatment for androgen-related diseases but needs more testing.